Literature DB >> 8645236

Functional coupling of adenosine A2a receptor to inhibition of the mitogen-activated protein kinase cascade in Chinese hamster ovary cells.

D Hirano1, Y Aoki, H Ogasawara, H Kodama, I Waga, C Sakanaka, T Shimizu, M Nakamura.   

Abstract

Activation of Gs-coupled receptors enhances the increase in cyclic AMP mediated by adenylate cyclases. As it has been shown that cyclic AMP inhibits the epidermal growth factor-activated mitogen-activated protein kinase (MAPK) signalling pathway, stimulation of Gs-coupled receptors may lead to the inhibition of MAPK activation. To investigate the effect of a Gs-coupled receptor on the MAPK cascade, we cloned the adenosine (Ado) A2a receptor from a guinea-pig leucocyte cDNA library, and established Chinese hamster ovary (CHO) cells stably expressing the receptor (CHOAdoA2R). The [3H]5'-N-ethylcarbamoyladenosine (NECA) binding characteristics (Kd = 91.0 +/- 5.4 nM, Bmax = 707 +/- 11 fmol/mg of protein, n = 3) and NECA-induced cyclic AMP production indicate that the cloned Ado A2a receptor was functionally expressed in the cells. In CHO cells, thrombin induced intracellular Ca2+ increase and MAPK activation through the intrinsic G-coupled receptor. In CHOAdoA2R cells, NECA partially inhibited thrombin-elicited MAPK activation. When combining NECA-treatment with 1,2-bis-(o-aminophenoxy)ethane-N,N,N',N'-tetra-acetic acid acetoxymethyl ester (BAPTA-AM) loading, a nearly complete inhibition of the MAPK activation occurred. Forskolin also partially inhibited the MAPK activation and synergized with BAPTA-AM, suggesting that partial inhibition of MAPK activation by NECA results from cyclic AMP production via Ado A2a receptor activation. The same synergism of MAPK inhibition between wortmannin and BAPTA-AM was observed, but not between wortmannin and NECA. These results suggest that cyclic AMP production through Ado A2a receptor inhibits thrombin-elicited MAPK activation by a Ca(2+)-independent/wortmannin-sensitive pathway in CHO cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645236      PMCID: PMC1217353          DOI: 10.1042/bj3160081

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

1.  Activation of the MAP kinase pathway by the protein kinase raf.

Authors:  L R Howe; S J Leevers; N Gómez; S Nakielny; P Cohen; C J Marshall
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

2.  The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product.

Authors:  C M Crews; A Alessandrini; R L Erikson
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

Review 3.  Adenosine receptors.

Authors:  G L Stiles
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

4.  A method for binding parameters estimation of A1 adenosine receptor subtype: a practical approach.

Authors:  V Casadó; T Martí; R Franco; C Lluis; J Mallol; E I Canela
Journal:  Anal Biochem       Date:  1990-01       Impact factor: 3.365

5.  Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid.

Authors:  L L Lin; A Y Lin; J L Knopf
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

6.  Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase.

Authors:  N G Anderson; J L Maller; N K Tonks; T W Sturgill
Journal:  Nature       Date:  1990-02-15       Impact factor: 49.962

7.  Raf-1 activates MAP kinase-kinase.

Authors:  J M Kyriakis; H App; X F Zhang; P Banerjee; D L Brautigan; U R Rapp; J Avruch
Journal:  Nature       Date:  1992-07-30       Impact factor: 49.962

8.  A mitogen-activated protein (MAP) kinase activating factor in mammalian mitogen-stimulated cells is homologous to Xenopus M phase MAP kinase activator.

Authors:  K Shirakabe; Y Gotoh; E Nishida
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

9.  Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells.

Authors:  R Seger; N G Ahn; J Posada; E S Munar; A M Jensen; J A Cooper; M H Cobb; E G Krebs
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

10.  Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors.

Authors:  B N Cronstein; R I Levin; M Philips; R Hirschhorn; S B Abramson; G Weissmann
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

View more
  5 in total

1.  P2Y(AC)(-)-receptor agonists enhance the proliferation of rat C6 glioma cells through activation of the p42/44 mitogen-activated protein kinase.

Authors:  P Claes; B Grobben; K Van Kolen; D Roymans; H Slegers
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

2.  Adenosine A(2A) receptor ligation inhibits osteoclast formation.

Authors:  Aránzazu Mediero; Firas M Kara; Tuere Wilder; Bruce N Cronstein
Journal:  Am J Pathol       Date:  2011-11-30       Impact factor: 4.307

3.  Activation of adenosine A(2A) receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFκB nuclear translocation.

Authors:  Aránzazu Mediero; Miguel Perez-Aso; Bruce N Cronstein
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

Review 4.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

Review 5.  Adenosine receptor signalling in Alzheimer's disease.

Authors:  Phuc N H Trinh; Jo-Anne Baltos; Shane D Hellyer; Lauren T May; Karen J Gregory
Journal:  Purinergic Signal       Date:  2022-07-23       Impact factor: 3.950

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.